Hepatitis B screening before rituximab therapy: a multicentre South Australian study of adherence.
Samuel A L HallAbdul ShaikhKailin TehMahsa TantiongcoDouglas CoghlanChris S KarapetisMohammad A ChinnarathaRichard WoodmanKate R MullerAlan J WiggPublished in: Internal medicine journal (2019)
Poor adherence to HBV screening protocols suggests the need for targeted clinician education and system redesign. While the rate of reactivation was low, the prevalence of at-risk patients in this population was high and justifies further initiatives to increase adherence rates to HBV screening pre-rituximab.
Keyphrases
- hepatitis b virus
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- healthcare
- newly diagnosed
- chronic kidney disease
- liver failure
- prognostic factors
- clinical trial
- glycemic control
- randomized controlled trial
- type diabetes
- cancer therapy
- cross sectional
- stem cells
- drug delivery
- metabolic syndrome
- patient reported outcomes
- mesenchymal stem cells
- cell therapy